Search
AT2220
go.drugbank.com/drugs/DB05200InvestigationalAT2220 has been shown to increase GAA activity in cell lines derived from Pompe patients and in transfected cells expressing misfolded forms of GAA.
SRP 299
go.drugbank.com/drugs/DB05440ExperimentalSRP 299 is a preparation of killed Mycobacterium vaccae that has been tested in uses related to inhibiting periodontal disease, in treating asthma and in treating eczema, itching and inflammation.
Medetomidine
go.drugbank.com/drugs/DB11428ExperimentalVet approvedThe drug has been developed by Orion Pharma. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health.
Sagopilone
go.drugbank.com/drugs/DB12391InvestigationalSagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others.
Olokizumab
go.drugbank.com/drugs/DB13127InvestigationalInterleukin-6 (IL-6) is an important cytokine with roles in immune cell proliferation/differentiation, energy and bone metabolism, and the acute phase response of the innate immune system. IL-6 pathway dysregulation is associated with ch...
TST10088
go.drugbank.com/drugs/DB05151ExperimentalTST10088 has been designed and engineered by Twinstrand to contain a peptide switch that is specifically cleaved by the matrix metalloproteinases which are known to be involved in tumor growth and metastasis
Briakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Ginsenoside Rg1
go.drugbank.com/drugs/DB06750ExperimentalNutraceuticalGinsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy.
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigational[L15302] It is produced using recombinant DNA technology in Chinese hamster ovary cells, and contains an IgG1/2 hybrid Fc-domain which has been modified with 2 amino acid substitutions to enhance its cytotoxicity
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system